



Contents lists available at ScienceDirect

## Asian Pacific Journal of Tropical Biomedicine

journal homepage: www.elsevier.com/locate/apjtb



Document heading

doi:10.12980/APJTB.4.2014C1133

© 2014 by the Asian Pacific Journal of Tropical Biomedicine. All rights reserved.

# Characteristics of bacterial sepsis among patients with visceral leishmaniasis

Mengistu Endris<sup>1\*</sup>, Yegnasew Takele<sup>2</sup>, Desalegn Woldeyohannes<sup>3,4</sup>, Chandrashekhar Unakal<sup>1</sup>, Feleke Moges<sup>1</sup>, Moges Tiruneh<sup>1</sup>, Ermias Diro<sup>5,6</sup>

<sup>1</sup>Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, University of Gondar, Ethiopia

<sup>2</sup>Leishmaniasis Research and Treatment Center, University of Gondar, Ethiopia

<sup>3</sup>Department of Immunology and Molecular Biology, School of Biomedical and Laboratory Sciences, University of Gondar, Ethiopia

<sup>4</sup>Department of Public Health, Addis Ababa Science and Technology University, Ethiopia

<sup>5</sup>Department of Internal Medicine, School of Medicine, University of Gondar, Ethiopia

<sup>6</sup>Institute of Tropical Medicine, Antwerp, Belgium

## PEER REVIEW

### Peer reviewer

Zinaye Tekaste, Assistant Professor, Aklilu Lemma Institute of Pathobiology, Addis Ababa, Ethiopia.  
Tel: +251 911976957  
E-mail: zinzn98@yahoo.com

### Comments

This review is a valuable work in which authors have demonstrated that VL and VL–HIV co-infected patients which are affected by bacterial infections leading to sepsis, should be diagnosed and treated early. Optimal infection control measures should be timely taken in order to reduce nosocomial sepsis. Indwelling of central venous lines for immune-suppressed patients such as VL and VL–HIV co-infected should be reduced as much as possible.  
Details on Page 874

## ABSTRACT

Sepsis is one of the major causes and predictors of death in patients with visceral leishmaniasis (VL). Globally, incidence rate of sepsis ranged from 56–91 cases per 100000 people, with a mortality rate of 30%. Incidence of sepsis has been raised due to aging of the population and the higher incidence of immunosuppressive conditions such as HIV, VL and others. The prevalence of sepsis was reported from 4.2% to 32.3% and 14.1% in VL and VL–HIV coinfecting patients, respectively. The mortality rate of VL patients with sepsis is greater than 50%. Factors associated with sepsis in VL patients are immune suppression, pancytopenia, HIV co-infection, age <1 year old and >40 years old, indwelling of central venous lines and hospitalization. Although antimicrobial susceptibility patterns were not well reported, both Gram-positive and Gram-negative bacteria were isolated from patients with VL. So far, limited information is available on sepsis in VL, especially in VL–HIV coinfecting patients. Therefore, further studies about sepsis prevalence, causative agents and their antibiotic patterns, and associated factors among VL and VL–HIV coinfecting patients are necessary. This review provides information about bacterial sepsis in patients with VL.

## KEYWORDS

Sepsis, Visceral leishmaniasis, VL–HIV, HIV/AIDS

## 1. Introduction

Sepsis is defined as the presence or presumed presence of an infection accompanied by evidence of a systemic

response called the systemic inflammatory response syndrome[1]. Recently Vincent *et al.* defined as host's deleterious, non-resolving inflammatory response to infection that leads to organ dysfunction[2]. Although

\*Corresponding author: Mengistu Endris, Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, University of Gondar, P.O. Box 196, Gondar, Ethiopia.

Tel: +251-(0) 918-786365  
E-mail: mengistu06@gmail.com

Article history:

Received 25 Jan 2014

Received in revised form 22 Feb, 2nd revised form 13 Mar, 3rd revised form 16 Apr 2014

Accepted 23 May 2014

Available online 5 Sep 2014

sepsis can be caused by viruses and fungi, most is due to bacterial infections[3]. Recent review by Jawad *et al.* revealed that the incidence rate of sepsis ranged from 56–91 cases per 100 000 people, with a reported mortality rate of 30%[4]. Incidence of sepsis is increasing due to nosocomial infection, aging of the population and the higher incidence of immunosuppressive conditions such as HIV/AIDS[5], visceral leishmaniasis (VL) and VL–HIV co-infection and others[6–8].

VL is one of the most neglected infectious diseases[9]. Over 90% of the estimated annual incidence in half a million VL cases worldwide occur in just six countries which are Bangladesh, India, Nepal, Sudan, Ethiopia and Brazil[10–12]. The highest prevalence of VL–HIV co-infection in the world was reported from Eastern African region reached up to 40%[10,13].

Patients with VL usually present with fever, weight loss, organomegaly and pancytopenia. *Leishmania donovani*, etiologic agent of VL, targets reticuloendothelial system, spleen, liver, bone marrow and lymph nodes[9]. *Leishmania* invade and replicate within host macrophages, evading innate and cell-mediated immune responses. Patients with VL show a continuum of immune responses from protective to non-protective[14]. Leucopenia, malnutrition and lack protective responses to *Leishmania* and other antigens including bacteria, predispose patients with VL to bacterial infections[15,16].

Studies conducted on the prevalence of sepsis ranged from 3% to 28% among VL patients[6–8,17–21]. Although sepsis has high prevalence and affects the outcome of patients with VL, the causative agents and their antimicrobial susceptibility patterns are poorly understood. Under knowing the current magnitude of sepsis in immuno-compromised individuals such as VL and VL–HIV coinfecting patients, it is important to take rational management for them. This review, therefore aims to compile available information on the prevalence, associated risk factors and etiologic agents of bacterial sepsis in patients with VL and VL–HIV co-infection.

## 2. Methods

This review was developed after reviewing the pertinent information available about sepsis among patients with VL and VL–HIV co-infection from Hinari, Entrez–PubMed and Google Scholar web sites.

## 3. Sepsis

### 3.1. Prevalence of sepsis

The prevalence of sepsis in patients with VL and VL–HIV coinfecting patients in the world is not clearly known. Recent studies showed sepsis was a main factor that affected the treatment outcome of patients with VL[22]. Bacterial infections and sepsis among VL and VL–HIV coinfecting patients have been reported ranging from 15% to 84% and 3% to 28%, respectively (Table 1).

**Table 1**

Prevalence of bacterial infections and sepsis among patients with VL.

Country of study	Bacterial infections	Sepsis	Study group	Reference
Brazil	52.4%	NR	Admitted VL (n=63)	[24]
Brazil	60.0%	4.2%	Admitted VL (n=30)	[6]
Brazil	27.5%	9.1%	Paediatric VL (n=120)	[21]
Iran	41.0%	13.0%	Paediatric VL (n=54)	[7]
Albania	60.0%	NR	VL patients (n=50)	[25]
Albania	84.0%	3.0%	Admitted VL (n=1 210)	[20]
Iran	42.0%	28.0%	Paediatric VL (n=60)	[17]
Ethiopia	42.8%	5.0%	Non–HIV VL (n=247)	[8]
Ethiopia	23.1%	NR	Pediatric VL (n=77)	[26]
Ethiopia	15.0%	7.0%	All VL (n=81)	[18]
Ethiopia	16.0%+	10.0%+	Adult VL (n=241)	[19]
	40.0%++	14.0%++		

NR: Not reported, +: HIV negative, ++: HIV positive.

### 3.2. Associated risk factors

The increased susceptibility of VL patients to bacterial infections leads sepsis to be multi-factorial. Immunosuppression, leucopenia and malnutrition are the most important factors associated with susceptibility to bacterial infections[8,17]. Extreme age (age <1 year old and >40 years old) and HIV are the factors associated with bacterial sepsis[8]. Malnutrition, pulmonary rales, severe anemia, severe absolute neutropenia and higher neutrophil count were also identified as risk factors related to bacterial infections that lead to death in patients with VL[15]. Neutropenia associated with bacteremia is common in immuno-compromised patients including cancer patients[23].

Increased exposure to potentially resistant bacteria in nursing homes and utilization of insufficiently sterilized medical devices including indwelling catheters and central venous lines will also increase risks. Patients with VL treated in hospital had significantly higher rates of complications than those treated on outpatient basis ( $P<0.001$ )[8].

### 3.3. Sources for sepsis

The sources for sepsis are bacterial infections elsewhere in the body that include: lungs, wounds, soft tissues, central nervous system and urinary tract infections. Bacterial infections (such as pneumonia, otitis media, and gastrointestinal infections) cause sepsis, which are common in patients with VL ranging from 15% to 84%[6–8,17–21,24–26]. Patients with VL will stay in hospital for at least 30 d for the treatment of VL. In this period, they will be treated with the drugs (such as sodium stibogluconate, amphotericin b) intravenously. This intravenous dwelling may also contribute to the entrance of bacterial agents. A few studies in Ethiopia also reported bacterial infections ranging from 15% to 42.8% and 40% in patients with VL and VL–HIV co-infection, respectively[8,18,19,26].

### 3.4. Etiologic agents and their antimicrobial susceptibility patterns

Both Gram–positive and Gram–negative bacteria were isolated from patients with VL (Table 2). Among the Gram–positives, *Staphylococcus aureus* were the predominateing isolate. Unexpected Gram–negative bacteria such as *Shigella* was also reported from a VL case in Ethiopia[27]. Although some bacteria were isolated from patients with VL, their antimicrobial susceptibility patterns are not well studied (Table 2).

### 3.5. Mortality due to sepsis

Sepsis is a life–threatening disease that may lead to shock, multiple organ failure, and death, especially if not recognized early and treated promptly. Millions of

people die of sepsis every year worldwide[28]. Bloodstream infections are usually serious infections typically causing a prolonged hospital stay, increased cost and risk of mortality, especially when it occurs with other co–infections like HIV[29]. Sepsis is the primary cause of death that contributes 34% to 75% of the total deaths in patients with VL[18,20–22,26]. Bacterial sepsis still remains the primary cause of death from infection in spite of advanced modern medicine, including vaccines, antibiotics and acute care.

Sepsis was one of the associated factors with poor treatment outcome (death) in patients with VL and VL– HIV coinfectd. Patients with VL and sepsis have six times [odds ratio (OR)=6.44] more risk to die than with VL but not sepsis. In patients with VL–HIV coinfection and sepsis, this risk raises to nine times (OR=9.06)[19].

## 4. Conclusion

Sepsis is an important health problem causing death of VL and VL–HIV coinfectd patients. Sepsis in VL patients is associated with immune suppression, pancytopenia, HIV coinfection, age <1 year old and >40 years old, indwelling of central venous lines and hospitalization. Bacterial infections such as pneumonia, otitis media, and gastrointestinal infections leading to sepsis were common among VL patients. Both Gram–positive and Gram–negative bacteria were isolated from blood cultures of sepsis suspected VL patients. VL and VL–HIV coinfectd patients that are affected by bacterial infections (such as pneumonia, otitis media, gastrointestinal infections), which cause sepsis, should be diagnosed and treated early. Optimal infection control measures should be taken by concerned bodies in order to reduce nosocomial sepsis. Indwelling of central venous

**Table 2**

Bacterial agents isolated from blood culture of patients with VL and HIV co–infection.

Gram–reaction	Bacteria isolated	Case/total (%)	Susceptibility testing	Country	References
Gram–positives	<i>Staphylococcus aureus</i>	3/54 (5.6%)	DNR	Iran	[7]
		3/247 (1.2%)	ND	Ethiopia	[8]
	<i>Streptococcus pneumonia</i>	1*	ND	Spain	[30]
	<i>Acinetobacter baumannii</i>	1*	MDR	Greece	[31]
	<i>Enterobacter species</i>	1/24 (4.2%)	ND	Brazil	[6]
Gram–negatives		1/54 (1.9%)	DNR	Iran	[7]
	<i>Escherichia coli</i>	1*	ND	Spain	[30]
		1/247 (0.4%)	ND	Ethiopia	[8]
	<i>Klebsiella pneumonia</i>	2/54 (3.7%)	DNR	Iran	[7]
	<i>Pseudomonas aeroginasa</i>	1/54 (1.9%)	DNR	Iran	[7]
		1/247 (0.4%)	ND	Ethiopia	[8]
	<i>Shigella species</i>	1*	D	Ethiopia	[27]

\*: Case report, ND: not done, DNR: done but not reported, MDR: multiple drug resistant, D: done (sensitive to all tested except ampicillin).

lines for immunosuppressed patients such as VL and VL–HIV coinfection should be reduced as much as possible. It is necessary to further study about sepsis causative agents, their antibiotic pattern and associated factor among VL and VL–HIV coinfecting patients.

### Conflict of interest statement

We declare that we have no conflict of interest.

---

### Comments

#### Background

Sepsis is the presence of an infection accompanied by evidence of systemic inflammatory response syndrome. Incidence of sepsis is increasing due to nosocomial infection, aging of the population and the higher incidence of immunosuppressive conditions such as HIV/AIDS, VL and VL–HIV co-infection and others. VL is one of the neglected diseases in the world, affecting the poorest segment of rural populations. Studies have shown that the prevalence of sepsis ranged from 3% to 28% among VL patients. Therefore, knowing the current magnitude of sepsis in immuno-compromised individuals such as VL and VL–HIV co-infected patients is important for rational management of patients.

#### Research frontiers

As VL and VL–HIV co-infected patients are immunocompromised patients and studies showed that bacterial sepsis is becoming an important concern in this population segment. VL is one of the neglected diseases in developing countries where bacterial infection is equally important, hence addressing this problem may be important for increasing awareness of the community and give better attention for patient management.

#### Related reports

In recent reports sepsis was the main factor that affects the treatment outcome of patients with VL (Hussein *et al.*, 2001). Bacterial infections and sepsis among VL and VL–HIV co-infected patients have been reported ranging from 15% (Tadesse and Hurissa, 2009) to 84% (Petrela *et al.*, 2010) and 3% (Petrela *et al.*, 2010) to 28% (Barati *et al.*, 2008) respectively. Sepsis is the primary cause of death that contributes 34% to 75% of the total deaths in patients with

VL (Rocha *et al.*, 2011).

#### Innovations and breakthroughs

As VL and VL–HIV co-infected patients are immunocompromised patients, in the present study authors have demonstrated the importance of bacterial sepsis in this population segments which become important public health concern.

#### Applications

It has been found that sepsis is the primary cause of death that contributes to a significant number of deaths in patients with VL. Addressing this issue may be important for increasing awareness of the community and give better attention for patient management.

#### Peer review

This review is a valuable work in which authors have demonstrated that VL and VL–HIV co-infected patients affected by bacterial infections leading to sepsis, should be diagnosed and treated early. Optimal infection control measures should be timely taken in order to reduce nosocomial sepsis. Indwelling of central venous lines for immune-suppressed patients such as VL and VL–HIV co-infected should be reduced as much as possible.

---

### References

- [1] Vincent JL. Definition of sepsis and non-infectious SIRS. In: Cavallion JM, Adrie C, editors. *Sepsis and non-infectious systemic inflammation: from biology to critical care*. New Jersey, USA: Wiley Online Library; 2009, p. 1–5.
- [2] Vincent JL, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. *Lancet* 2013; **381**: 774–775.
- [3] Tortora GJ, Funke BR, Case CL. Microbiology: an introduction. In: Berriman L, Pille R, Heimsoth K, Reed K, Earl W, editors. *Principles of disease and epidemiology*. 10th ed. San Francisco, USA: Pearson Education; 2010, p. 639–642.
- [4] Jawad I, Lukšić I, Rafnsson SB. Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. *J Glob Health* 2012; **2**(1): 010404.
- [5] Naufal Spir PR, Zampieri D'Andrea LA, Fonseca ES, Prestes-Carneiro LE. Epidemiology of human immunodeficiency virus–visceral leishmaniasis–co-infection. *J Microbiol Immunol Infect* 2013; doi: 10.1016/j.jmii.2013.05.002.
- [6] Andrade TM, Carvalho EM, Rocha H. Bacterial infections in patients with visceral leishmaniasis. *J Infect Dis* 1990; **162**(6): 1354–1359.

- [7] Kadivar MR, Kajbaf TZ, Karimi A, Alborzi A. Childhood visceral leishmaniasis complicated by bacterial infections. *East Mediterr Health J* 2000; **6**: 879–883.
- [8] Berhe N, Hailu A, Abraham Y, Tadesse Y, Breivik K, Abebe Y. Inter-current and nosocomial infections among visceral leishmaniasis patients in Ethiopia: an observational study. *Acta Trop* 2001; **80**(2): 87–95.
- [9] van Griensven J, Diro E. Visceral leishmaniasis. *Infect Dis Clin North Am* 2012; **26**: 309–322.
- [10] Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, et al. The relationship between leishmaniasis and AIDS: the second 10 years. *Clin Microbiol Rev* 2008; **21**(2): 334–359.
- [11] World Health Organization. Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the control of leishmaniasis. Geneva, Switzerland: World Health Organization; 2010. [Online] Available from: [http://whqlibdoc.who.int/trs/WHO\\_TRS\\_949\\_eng.pdf](http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf) [Accessed on 17th October, 2013]
- [12] Alvar J, Vélez ID, Bern C, Herrero Mé, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. *PLoS One* 2012; **7**(5): e35671.
- [13] Diro E, Hailu A, Lynen L, Boelaert M, van Griensven J. VL–HIV co-infection in East–Africa: current challenges and perspectives. Barcelona, Spain: 7th European Congress on Tropical Medicine and International Health; 2011, p. 17.
- [14] Bogdan C. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. *Cell Microbiol* 2008; **10**(6): 1221–1234.
- [15] Costa CH, Werneck GL, Costa DL, Holanda TA, Aguiar GB, Carvalho AS, et al. Is severe visceral leishmaniasis a systemic inflammatory response syndrome? A case control study. *Rev Soc Bras Med Trop* 2010; **43**(4): 386–392.
- [16] Pearson R, De Queiroz Souza A, Jeronimo S. Leishmania species: visceral (kala-azar), cutaneous, and mucosal leishmaniasis. In: Mandell GL, Bennett JE, Dolin R, editors. *Principles and practice of infectious diseases*. 5th ed. Philadelphia: Churchill Livingstone; 2000, p. 2831–2841.
- [17] Barati M, Sharifi I, Daie Parizi M, Fasihi Harandi M. Bacterial infections in children with visceral leishmaniasis: observations made in Kerman province, southern Iran, between 1997 and 2007. *Ann Trop Med Parasitol* 2008; **102**(7): 635–641.
- [18] Tadesse A, Hurissa Z. Leishmaniasis (PKDL) as a case of immune reconstitution inflammatory syndrome (IRIS) in HIV–positive patient after initiation of anti-retroviral therapy (ART). *Ethiop Med J* 2009; **47**(1): 77–79.
- [19] Hurissa Z, Gebre–Silassie S, Hailu W, Tefera T, Lalloo DG, Cuevas LE, et al. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. *Trop Med Int Health* 2010; **15**(7): 848–855.
- [20] Petrela R, Kuneshka L, Foto E, Zavalani F, Gradoni L. Pediatric visceral leishmaniasis in Albania: a retrospective analysis of 1,210 consecutive hospitalized patients (1995–2009). *PLoS Negl Trop Dis* 2010; **4**(9). doi: 10.1371/journal.pntd.0000814.
- [21] Rocha NA, Silva GB, Oliveira MJ, Abreu KL, Franco LF, Silva MP, et al. Visceral leishmaniasis in children: a cohort of 120 patients in a metropolitan city of Brazil. *Turk J Pediatr* 2011; **53**(2): 154–160.
- [22] Madalosso G, Fortaleza CM, Ribeiro AF, Cruz LL, Nogueira PA, Lindoso JA. American visceral leishmaniasis: factors associated with lethality in the state of são paulo, Brazil. *J Trop Med* 2012; doi: 10.1155/2012/281572.
- [23] Aydemir H, Piskin N, Kokturk F, Gökmen A, Akduman D. Health–care associated bacteremia in geriatric cancer patients with febrile neutropenia. *J Geriatr Oncol* 2013; **4**(2): 190–195.
- [24] Guerreiro J, Ribeiro S, Carvalho EM, Badaró R, Rocha H. [Bacterial infection in patients with visceral leishmaniasis]. *Mem Inst Oswaldo Cruz* 1985; **80**(4): 447–452. Portuguese.
- [25] Lita G, Davachi F, Sulcebe G, Bregu H, Basha M. Pediatric visceral leishmaniasis in Albania. *Int J Infect Dis* 2002; **6**(1): 66–68.
- [26] Yifru S, Wasie B. Clinical pattern of visceral leishmaniasis in paediatric age group, Northwest Ethiopia. *Ethiop J Health Biomed Sci* 2008; **1**(1): 23–29.
- [27] Endris M, Mohammed R, Takele Y, Woldeyohannes D, Tiruneh M, Diro E. *Shigella* bacteremia in a patient with visceral leishmaniasis. *Case Rep Crit Care* 2013; doi: 10.1155/2013/920729.
- [28] Marshall JC, Reinhart K. The global sepsis Alliance: building new collaborations to confront an under-recognized threat. *Surg Infect (Larchmt)* 2011; **12**(1): 1–2.
- [29] O’Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. *Clin Infect Dis* 2011; **52**(9): e162–e193.
- [30] Garcés JM, Tomás S, Rubiés–Prat J, Gimeno JL, Drobnic L. Bacterial infection as a presenting manifestation of visceral leishmaniasis. *Rev Infect Dis* 1990; **12**(3): 518–519.
- [31] Mpaka MA, Daniil Z, Kyriakou DS, Zakynthinos E. Septic shock due to visceral leishmaniasis, probably transmitted from blood transfusion. *J Infect Dev Ctries* 2009; **3**(6): 479–483.